Johnson & Johnson (JNJ)

$267.24 +7.91 (3.05%)
Market Cap 624.26B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.51
Forward PE 22.74
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 9,089,600
Avg Vol 8,194,836
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 93%
Beta 0.24
Analysts Strong Sell
Price Target $260.04

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 9:13 AM
$JNJ approaching first target of 271.37 in expected rally within 6.22.2026 low It should see more upside up to 305.2, while dips remain supported in 3. 7 or 11 swings within May-2026 sequence as bull run. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave
0 · Reply
theoptionsplug
theoptionsplug Jul. 8 at 6:11 AM
THINGS TO WATCH, WEDNESDAY, 7/8/2026 👁️ $LEVI $HELE $JNJ $AVAV $SPY
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 2:27 AM
$JNJ Current Stock Price: $267.28 Contracts to trade: $267.5 JNJ Jul 10 2026 Call Entry: $2.62 Exit: $3.65 ROI: 39% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 1:22 AM
$JNJ continue rally targeting 271.4 - 305.3 area against 6.23.2026 low It is bullish in daily & expect rally within January-2025 low to continue against May-2026 low. Short term pullback in 3, 7 or 11 swings remain supported. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Onestockatatime20
Onestockatatime20 Jul. 7 at 10:54 PM
$CMPS $DFTX $JNJ
0 · Reply
Quantumup
Quantumup Jul. 7 at 8:59 PM
Stifel⬆️ $CMPS to $21 from $14,⬆️peak gross revenue to $1.5B and reiterated Buy -- Sees room for multiple winners—expects substantial patient demand for '360. $DFTX $JNJ HELP Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2074598446774788361?s=20
0 · Reply
TalkMarkets
TalkMarkets Jul. 7 at 8:32 PM
Unusual Put Option Activity In #JohnsonJohnson After JNJ Stock's Recent Runup $JNJ https://talkmarkets.com/article/unusual-put-option-activity-in-johnson-johnson-after-jnj-stocks-recent-runup-1783456297
0 · Reply
EquityClock
EquityClock Jul. 7 at 6:17 PM
Nice move in Pharmaceutical stocks today, an Accumulate candidate in our work. The industry is within its optimal holding period that runs between May and September. $IHE $PFE $LLY $JNJ
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 5:32 PM
$JNJ Where was Cramer @ $90-$100 ?? lol Now he tels peoples to buy here... because it's so "cheap" lol
0 · Reply
Quantumup
Quantumup Jul. 7 at 5:12 PM
BTIG⬆️ $CMPS to $25 from $14, reitd Buy/said suicide was bound to happen=part of the TRD landscape/that unfortunate reality was also driven home by today's readout—doesn't view this event as more than headline noise considering what was seen w/ Spravato. $JNJ $HELP DFTX Here's what BTIG had to say: https://x.com/Quantumup1/status/2074541548759322998?s=20
0 · Reply
Latest News on JNJ
Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 1 day ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Johnson & Johnson price target raised to $290 from $280 at HSBC

2026-07-06T14:25:32.000Z - 1 day ago

Johnson & Johnson price target raised to $290 from $280 at HSBC

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 11 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

2026-06-26T16:40:11.000Z - 11 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 11 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-26T12:36:03.000Z - 11 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

2026-06-25T09:10:22.000Z - 13 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 13 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

2026-06-16T20:26:11.000Z - 21 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T11:17:46.000Z - 22 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

Johnson & Johnson invests more than $1B in Jacksonville, Florida

2026-06-15T10:05:07.000Z - 22 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 23 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 24 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 24 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

2026-06-11T11:50:10.000Z - 26 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 26 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 26 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 27 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 27 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 27 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 4 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 4 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 5 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 5 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 5 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 5 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 5 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 5 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 5 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 6 weeks ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 7 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 2 months ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 27, 2026, 8:03 AM EDT - 2 months ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 9:13 AM
$JNJ approaching first target of 271.37 in expected rally within 6.22.2026 low It should see more upside up to 305.2, while dips remain supported in 3. 7 or 11 swings within May-2026 sequence as bull run. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave
0 · Reply
theoptionsplug
theoptionsplug Jul. 8 at 6:11 AM
THINGS TO WATCH, WEDNESDAY, 7/8/2026 👁️ $LEVI $HELE $JNJ $AVAV $SPY
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 2:27 AM
$JNJ Current Stock Price: $267.28 Contracts to trade: $267.5 JNJ Jul 10 2026 Call Entry: $2.62 Exit: $3.65 ROI: 39% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 1:22 AM
$JNJ continue rally targeting 271.4 - 305.3 area against 6.23.2026 low It is bullish in daily & expect rally within January-2025 low to continue against May-2026 low. Short term pullback in 3, 7 or 11 swings remain supported. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Onestockatatime20
Onestockatatime20 Jul. 7 at 10:54 PM
$CMPS $DFTX $JNJ
0 · Reply
Quantumup
Quantumup Jul. 7 at 8:59 PM
Stifel⬆️ $CMPS to $21 from $14,⬆️peak gross revenue to $1.5B and reiterated Buy -- Sees room for multiple winners—expects substantial patient demand for '360. $DFTX $JNJ HELP Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2074598446774788361?s=20
0 · Reply
TalkMarkets
TalkMarkets Jul. 7 at 8:32 PM
Unusual Put Option Activity In #JohnsonJohnson After JNJ Stock's Recent Runup $JNJ https://talkmarkets.com/article/unusual-put-option-activity-in-johnson-johnson-after-jnj-stocks-recent-runup-1783456297
0 · Reply
EquityClock
EquityClock Jul. 7 at 6:17 PM
Nice move in Pharmaceutical stocks today, an Accumulate candidate in our work. The industry is within its optimal holding period that runs between May and September. $IHE $PFE $LLY $JNJ
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 5:32 PM
$JNJ Where was Cramer @ $90-$100 ?? lol Now he tels peoples to buy here... because it's so "cheap" lol
0 · Reply
Quantumup
Quantumup Jul. 7 at 5:12 PM
BTIG⬆️ $CMPS to $25 from $14, reitd Buy/said suicide was bound to happen=part of the TRD landscape/that unfortunate reality was also driven home by today's readout—doesn't view this event as more than headline noise considering what was seen w/ Spravato. $JNJ $HELP DFTX Here's what BTIG had to say: https://x.com/Quantumup1/status/2074541548759322998?s=20
0 · Reply
Quantumup
Quantumup Jul. 7 at 4:46 PM
Oppenheimer reiterated $CMPS Outperform-$20 and said—We view the Ph3 COMP006 26-week data as reinforcing the durable efficacy profile of COMP360 (psilocybin), representing a transformative approach for the ~4M addressable TRD patients. $JNJ $DFTX HELP Here's what else Oppenheimer had to say: https://x.com/Quantumup1/status/2074535133391044982?s=20
0 · Reply
23ChaseColeman23
23ChaseColeman23 Jul. 7 at 4:41 PM
$TLT Bob seechan says The real diversified in portfolios are $KO $MCD $JNJ $WMT Not 20-30 year fixed income treasury government bonds
0 · Reply
CedarPark
CedarPark Jul. 7 at 4:26 PM
$TGTX Welp we are over the all-time highs now... SOoooo that means every short seller is under water and losing his backside. Margin calls and forced short covering on the way. $JNJ, $LLY, etc on the way to buy this..
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 7 at 3:37 PM
$TGTX With patent cliff issues and competition, BIG PHARMA keeping its money in the bank will not ensure its success and prosperity. Regarding TGTX, the BP with leadership that has vision, creativity, and willingness to act will be victorious. The other shareholders could then be saying to their leadership time is money and – How the heck did you miss that which was right before our and - most importantly - your eyes! $ABBV $JNJ $BMY
0 · Reply
Quantumup
Quantumup Jul. 7 at 3:05 PM
Jefferies reiterated $CMPS Buy-$18 and said -- It Remains 75-85%+ Confident the FDA Approves COMP360 YE26/Early-27 $JNJ $DFTX HELP Here's what else Jefferies had to say: https://x.com/Quantumup1/status/2074509775828636004?s=20
1 · Reply
TraderDaKing
TraderDaKing Jul. 7 at 2:33 PM
$ELTP $GME $TSLA $JNJ $WEN Here We go !!!!! Its an Elite Life for me...... Go ELTP Go ELTP................ One dollar... here we come.
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 2:26 PM
$JNJ When Cramer say Buy @ 5 years high.... You...Well you know !! https://www.cnbc.com/2026/07/06/jim-cramer-stocks-buy-during-market-rotation.html
0 · Reply
JFDI
JFDI Jul. 7 at 2:24 PM
$JNJ what a monster move
0 · Reply
StockBraker
StockBraker Jul. 7 at 2:15 PM
$JNJ New 52 week high.
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 1:59 PM
$JNJ $ABBV I'm taking 50% profits on both !! Thanks USA !!
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 7 at 1:56 PM
$ELTP $PFE $JNJ $MRNA $GME
0 · Reply
biolover
biolover Jul. 7 at 1:49 PM
$LLY $VKTX on the hands of $ABBV I beleive partnership is happening soon. This dyslocatuon in obesity market can’t continue forever. Not all managments as blind as $MRK and $JNJ
0 · Reply